Clinical Characteristics of Seven Patients with Lanthanum Phosphate Deposition in the Stomach

Naoko Murakami¹, Masao Yoshioka¹, Masaya Iwamuro²,³, Junichirou Nasu¹, Soichiro Nose⁴, Junji Shiode¹, Hiroyuki Okada² and Kazuhide Yamamoto¹

Abstract:
Objective To analyze the clinical characteristics and endoscopic features of patients with lanthanum deposition in the stomach.
Patients We retrospectively reviewed seven patients with lanthanum deposition in the stomach who were diagnosed at Okayama Saiseikai General Hospital. We investigated the patient sex, age at diagnosis, medical and medication histories, gastrointestinal symptoms, complications, presence or absence of gastric atrophy, and outcome. We also investigated any changes in the endoscopic features if previous endoscopic images were available.
Results Seven patients (six males and one female) had lanthanum deposition. The median age was 65 years (range, 50-79 years). All patients had been undergoing dialysis (continuous ambulatory peritoneal dialysis in one patient, hemodialysis in six patients). The dialysis period ranged from 16 to 73 months (median, 52 months). The patients had all been taking lanthanum carbonate for a period ranging from 5 to 45 months (median, 27 months). Gastric atrophy was noted in 6 patients (85.7%). One patient had difficulty swallowing, and 1 other patient had appetite loss. The other 5 patients were asymptomatic. Endoscopic features included annular whitish mucosa (n = 4), diffuse whitish mucosa (n = 3), and whitish spots (n = 2). Five patients underwent multiple esophagogastroduodenoscopy. The endoscopic features were unchanged in 2 patients, whereas the whitish mucosa became apparent and spread during the course in 3 patients.
Conclusion We identified 7 patients with lanthanum deposition in the stomach. All patients showed whitish lesions macroscopically. Although the pathogenicity of gastric lanthanum deposition is uncertain, lanthanum-related lesions in the stomach progressed during continuous lanthanum phosphate intake in several patients.

Key words: lanthanum carbonate, hyperphosphatemia, chronic kidney disease

(Intern Med 56: 2089-2095, 2017)
(DOI: 10.2169/internalmedicine.8720-16)

Introduction

Lanthanum carbonate, La₂(CO₃)₃, has been widely used to treat hyperphosphatemia in patients with chronic kidney disease because this agent has a higher efficacy and tolerability compared to other conventional phosphate binders (1-5). After consuming lanthanum carbonate with meals, lanthanum binds with dietary phosphate. As a result, the formation of highly insoluble complexes, such as lanthanum phosphate, occurs, and prevents phosphate absorption via the intestine. The gastrointestinal tract minimally absorbs lanthanum phosphate complexes; therefore, most of the lanthanum phosphate is excreted via the feces (6, 7). Despite its low bioavailability, accumulating evidence shows that lanthanum can be deposited in the gastrointestinal mucosa, particularly in the stomach (8-15). However, the endoscopic features of gastric lanthanum deposition have not yet been fully eluci-
The purpose of this study was to investigate the macroscopic features of lanthanum phosphate deposition in the stomach, with a particular focus on the sequential changes of the gastric mucosa over the course of continuous lanthanum carbonate use.

Materials and Methods

A database search of medical charts at Okayama Saiseikai General Hospital found 90 patients prescribed with lanthanum carbonate between January 2013 and February 2016. Biopsy was performed in 9 of the 90 patients during esophagogastroduodenoscopy examinations to investigate the possible presence of neoplasms, amyloid deposition, or lanthanum deposition. As a result, lanthanum deposition was histologically diagnosed in 7 patients. Thus, 7 patients were retrospectively registered in this study. Lanthanum deposition was histologically diagnosed based on the presence of fine, amorphous, eosinophilic material on hematoxylin and eosin-stained tissue slides (Fig. 1A). The presence of histiocytes was also identified by CD68 staining (Fig. 1B) in all cases. In 1 patient, scanning electron microscopy and energy-dispersive X-ray spectroscopy were used for the chemical analysis, as described in a previous study (16). Briefly, the deposited material on osmium-coated samples appeared bright in the scanning electron microscopy observation (Fig. 1C). We confirmed lanthanum (Fig. 1D) and phosphate distribution (Fig. 1E), which was identical to that of the bright areas, in elemental mapping images by using energy-dispersive X-ray spectroscopy.

Results

We retrospectively examined the following to determine each patient’s background: patient sex, age at diagnosis, medical, and medication histories including lanthanum carbonate intake, the infection status of Helicobacter pylori, gastrointestinal symptoms, gastrointestinal complications possibly related to lanthanum deposition, and the outcome. The presence or absence of gastric atrophy was endoscopically evaluated based on the mucosal color and structure of the stomach. Each patient’s endoscopic images in the database were reviewed and analyzed by two board-certified endoscopists (NM and MY). We subdivided each patient’s endoscopic features into three types as follows: (i) whitish spot(s) (whitish lesion ≤2 cm in diameter with a uniform white color) (Fig. 2A and B), (ii) annular whitish mucosa (lesion ≤2 cm in diameter with a white color in the periphery) (Fig. 2C and D), and (iii) a diffuse whitish mucosa (>2 cm in diameter, reddish areas may be intermixed in this lesion) (Fig. 2E). Sequential changes of the endoscopic features were also investigated in patients with multiple histories of undergoing endoscopic examinations.
phosphate was 27 months, ranging from 5 to 45 months. The *H. pylori* infection status was examined in only two patients. Both patients were positive for *H. pylori*, which was confirmed by serum antibodies against *H. pylori* in one patient and by a pathological analysis of gastric biopsy samples in the other patient. Gastric atrophy was endoscopically present in 6 of the 7 cases (85.7%). With regard to the gastrointestinal symptoms, difficulty in swallowing was documented in one patient, and one other patient had appetite loss. The other 5 patients were asymptomatic.

An annular whitish mucosa was identified in 4 patients, diffuse whitish mucosa in 3 patients, and whitish spots in 2 patients (Fig. 2-5) (Table 2). Five patients underwent esophagogastrroduodenoscopy twice or more. The endoscopic features were unchanged in 2 patients. The interval of esophagogastrroduodenoscopy was 9 months in these 2 patients. In the remaining 3 patients, a whitish mucosa became apparent and spread during the course in a time-dependent manner.

In case 1, esophagogastrroduodenoscopy performed 4 months before the start of lanthanum carbonate prescription showed no whitish lesions in the stomach (Fig. 3A and B). After lanthanum carbonate intake for 20 months, a diffuse whitish mucosa was seen in the gastric cardia (Fig. 3C). Multiple round, slightly elevated areas with reddish part in its center and whitish part in its periphery were also identified in the gastric antrum (Fig. 3D). Thirty-eight months after the start of lanthanum phosphate administration, the dif-

---

**Figure 2.** Endoscopy images. Representative endoscopy images of whitish spots (A, B), an annular whitish mucosa (C, D), and a diffuse whitish mucosa (E). Case 3 has whitish spots (A, arrow), which resemble gastric xanthoma, in addition to a diffuse whitish mucosa (Fig. 5). Similar whitish spots are seen in case 7 (B, arrow). An annular whitish mucosa is seen in case 4 (C, arrow) and case 5 (D, arrow). Case 1 has a diffuse whitish mucosa (E).

**Table 1. Clinical Background of the Study Subjects with Lanthanum Deposition in the Stomach.**

| No. | Age at diagnosis (years) | Sex | Type of dialysis | Period of taking lanthanum carbonate (months) | *Helicobacter pylori* infection | Gastric atrophy | Gastrintestinal symptoms |
|-----|--------------------------|-----|------------------|---------------------------------------------|-----------------------------|-----------------|------------------------|
| 1   | 50                       | M   | CAPD             | 36                                          | Positive (serology)         | Present         | Difficulty swallowing |
| 2   | 50                       | F   | HD               | 73                                          | Positive (histology)        | Present         | None                   |
| 3   | 65                       | M   | CAPD, HD         | 59                                          | NA                          | Present         | None                   |
| 4   | 73                       | M   | CAPD             | 16                                          | NA                          | Present         | Appetite loss          |
| 5   | 79                       | M   | CAPD             | 52                                          | NA                          | Absent          | None                   |
| 6   | 67                       | M   | CAPD             | 29                                          | NA                          | Present         | None                   |
| 7   | 56                       | M   | CAPD, HD         | 68                                          | NA                          | Present         | None                   |

CAPD: continuous ambulatory peritoneal dialysis, HD: hemodialysis, NA: not available
fuse whitish mucosa in the gastric cardia seemed to have expanded (Fig. 3E). Moreover, multiple round lesions in the gastric antrum became apparent (Fig. 3F).

In case 2, a 50-year-old female, who had been taking lanthanum carbonate for 36 months was diagnosed with lanthanum deposition in the stomach (Fig. 4A). Fifty-six months after taking lanthanum carbonate, a diffuse whitish mucosa with partial redness was seen predominantly in the lesser curvature of the gastric body, which became more apparent and spread during the course (Fig. 4B).

In case 3, esophagogastroduodenoscopy performed 4 months after lanthanum carbonate intake showed a slightly whitish area in the posterior wall of the gastric body, which seemed to have resulted from intestinal metaplasia (Fig. 5A). Biopsy sampling was not performed at that time. Apparent whitish lesions emerged, which were intermingled with reddish areas, 32 months later (Fig. 5B). Lanthanum deposition was detected in the biopsy samples of the diffuse whitish mucosa.
In Japan, a chewable tablet form of lanthanum carbonate was released to the market in March 2009. In addition, lanthanum carbonate granules have been marketed since May 2012. Other phosphate-binding modulators include calcium carbonate, sevelamer hydrochloride, bixalomer, and ferric citrate. The phosphorus removal effect of calcium carbonate decreases as the intragastric pH increases. In contrast, lanthanum carbonate shows a high phosphorus removal effect irrespective of the intragastric pH levels (17). Therefore, lanthanum carbonate is effective for treating hyperphosphatemia even under acid secretion inhibitor administration. Although gastrointestinal symptoms, such as nausea, vomiting, and constipation, may appear as side effects, lanthanum carbonate has been widely used based on its safety and tolerability as described above.

Orally administered lanthanum binds with phosphorus in the diet and forms lanthanum phosphate, finally being excreted via the feces, as described in the Introduction section. However, since 2015, lanthanum has been reported to be phagocytosed by macrophages and deposited in the gastric mucosa as lanthanum phosphate (8-16). Previous reports described gastric and duodenal lesions associated with lanthanum phosphate deposition as white lesions, which were found during esophagastroduodenoscopy. The white color may be caused by the aggregated particles of lanthanum phosphate itself, as demonstrated by microscopy and scanning electron microscopy (Fig. 1). Another hypothesis is that the white color reflects histiocytes entrapping lanthanum phosphate. The similarity in the color between the lanthanum deposition and gastric xanthoma, which consists of clusters of foamy histiocytes, supports the latter hypothesis. Differential diagnoses of whitish lesions in the stomach include extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) (18), plasmacytoma (19), and crystal-storing histiocytosis (20), in addition to xanthoma. Intestinal metaplasia is often visible as whitish plaques as well. Magnifying observations may be helpful to distinguish these disorders from lanthanum phosphate deposition. However, the value of magnifying observation for diagnosing this entity is beyond the scope of this study and thus will require further investigation. At the present time, endoscopic biopsy and appropriate pathological analyses are essential.

In the present study, lanthanum deposition in the stomach was observed as an annular whitish mucosa (n=4), diffuse whitish mucosa (n=3), and whitish spots (n=2). Although we determined the presence of gastric atrophy based on endoscopic features alone rather than based on pathological evaluations, all but one patient had atrophic gastritis. Consequently, one possible explanation of such a multifarious presentation of lanthanum induced gastric lesions is that...
these lesions reflect underlying gastric mucosal alterations caused by chronic gastritis. Tonooka et al. reported a patient with lanthanum deposition in the stomach, in whom lanthana- num trapped in macrophages was found mainly in the atro- phic mucosa with metaplastic epithelia (8). They also men- tioned another patient who had taken lanthanum carbonate for years and showed no atrophy, intestinal metaplasia, or lanthanum deposition in the stomach. The authors speculated that differences in the tight junction structure and increased permeability of the intestinal metaplasia may lead to lantha- num deposition or absorption in the gastric mucosa. How- ever, because of the small number of reported patients, the primary factor affecting the macroscopic features of lanthanum-induced gastric lesions still remains unknown.

This is the first study showing the chronologic changes of lanthanum-related lesions in the stomach over the course of lanthanum carbonate administration. Repeat esophagogastro- duodenoscopy examinations revealed that whitish lesions in the stomach became apparent and had spread during the course in three patients (Fig. 2-4). Although the endoscopic features were unchanged in the other 2 patients, the interval between endoscopy examinations was 9 months in both pa- tients. Therefore, if endoscopic examinations had been performed after a longer time interval, then the macroscopic features of gastric lesions in these 2 patients might have changed. Our study results indicate that lanthanum deposi- tion in the gastric mucosa probably progresses in a time- dependent manner, as long as this agent is prescribed.

Several components of various drugs have been known to be deposited in the gastroduodenal mucosa in patients with chronic kidney disease. A change in the mucosal color to black in patients taking diuretics or antihypertensive agents is known to be associated with pseudomelanosis (21, 22). Pseudomelanosis is generally not considered a contraindica- tion for any administered drug, because this occurrence is considered to be harmless. In contrast, the pathological sig- nificance of lanthanum deposition in the gastrointestinal mu- cosa has not yet been elucidated. In the present study, one patient complained of difficulty in swallowing, while an- other patient had appetite loss before undergoing esophagogastroduodenoscopy. However, the relationship be- tween their symptoms and lanthanum deposition remains un- certain, because such symptoms are non-specific and can oc- cur after the ingestion of lanthanum carbonate itself or due to some other causes. No known treatment or specific follow-up protocols have yet been established in previously described cases as well.

Rothenberg et al. reported a histological improvement of lanthanum deposition in the stomach and duodenum 3 months after discontinuing lanthanum carbonate intake (10). Yabuki et al. reported that lanthanum deposition was identi- fied in the gastric mucosa in 3 patients with chronic renal failure who had undergone gastrectomy and lymph node dis- section due to gastric cancer. They also detected lanthanum deposition in the peripheral lymph nodes, suggesting that lanthanum deposited on the gastrointestinal mucosa may be removed via the lymphatic flow (15). Meanwhile, Namie et al. reported that the endoscopic findings remained un- changed even 8 months after the discontinuing lanthanum carbonate administration (23), thus indicating that lanthanum-related lesions may be irreversible once deposited in the gastrointestinal mucosa. Further investigation is re- quired to determine whether lanthanum deposition decreases or remains unchanged after the cessation of lanthanum car- bonate intake.

In summary, we retrospectively investigated 7 patients with lanthanum phosphate deposition in the stomach. Lanthanum-related gastric lesions were observed as an annu- lar whitish mucosa (n=4), diffuse whitish mucosa (n=3), and whitish spots (n=2). The progression of such lesions over time was observed in 3 patients. Although the clinical sig- nificance and long-term sequelae of this entity are unclear, endoscopists and gastroenterologists should include lantha- num deposition in the differential diagnosis when whitish le- sions are found during esophagogastroduodenoscopy.

The authors state that they have no Conflict of Interest (COI).

Acknowledgement

We thank Mr. Haruo Urata (Central Research Laboratory, Okayama University Medical School) for his important contribu- tions to the scanning electron microscopy analysis and energy dispersive X-ray spectroscopy analysis.

References

1. Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 19: 303-317, 1992.
2. Shigematsu T. Lanthanum Carbonate Research Group. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis. Ther Apher Dial 14: 12-19, 2010.
3. Tsuchida K, Nagai K, Yokota N, Minakuchi J, Kawashima S. Im- pact of lanthanum carbonate on prognosis of chronic hemodialysis patients: a retrospective cohort study (Kawashima Study). Ther Apher Dial 20: 142-148, 2016.
4. Cernaro V, Santoro D, Lacquaniti A, et al. Phosphate binders for the treatment of chronic kidney disease: role of iron oxihydroxide. Int J Nephrol Renovasc Dis 9: 11-19, 2016.
5. Giotta N, Marino AM. Pharmacoeconomic analysis: analysis of cost-effectiveness of lanthanum-carbonate (Lc) in uncontrolled hyperphosphatemia in dialysis. Value Health 18: A511, 2015.
6. Pennick M, Dennis K, Damment SJ. Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J Clin Pharmacol 46: 738-746, 2006.
7. Zhang C, Wen J, Li Z, Fan J. Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review. BMC Nephrol 14: 226, 2013.
8. Tonooka A, Uda S, Tanaka H, Yao A, Uekusa T. Possibility of lanthanum absorption in the stomach. Clin Kidney J 8: 572-575, 2015.
9. Makino M, Kawaguchi K, Shimojo H, Nakamura H, Nagasawa M, Kodama R. Extensive lanthanum deposition in the gastric mucosa: the first histopathological report. Pathol Int 65: 33-37, 2015.
10. Rothenberg ME, Araya H, Longacre TA, Pasricha PJ. Lanthanum- induced gastrointestinal histiocytes. ACG Case Rep J 2: 187-189.
11. Haratake J, Yasunaga C, Ootani A, Shimajiri S, Matsuyama A, Hisaoka M. Peculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonate. Am J Surg Pathol 39: 767-771, 2015.

12. Goto K, Ogawa K. Lanthanum deposition is frequently observed in the gastric mucosa of dialysis patients with lanthanum carbonate therapy: a clinicopathologic study of 13 cases, including 1 case of lanthanum granuloma in the colon and 2 nongranulomatous gastric cases. Int J Surg Pathol 24: 89-92, 2016.

13. Yasunaga C, Haratake J, Ohtani A. Specific accumulation of lanthanum carbonate in the gastric mucosal histiocytes in a dialysis patient. Ther Apher Dial 19: 622-624, 2015.

14. Iwamuro M, Sakae H, Okada H. White gastric mucosa in a dialysis patient. Gastroenterology 150: 322-323, 2016.

15. Yabuki K, Shibata E, Harada H, et al. Lanthanum deposition in the gastrointestinal mucosa and regional lymph nodes in dialysis patients: analysis of surgically excised specimens and review of the literature. Pathol Res Pract 212: 919-926, 2016.

16. Iwamuro M, Urata H, Tanaka T, et al. Lanthanum deposition in the stomach: usefulness of scanning electron microscopy for its detection. Acta Med Okayama 71: 73-78, 2017.

17. Coppolino G, Lucisano S, Rivoli L, et al. Sevelamer hydrochloride, sevelamer carbonate and lanthanum carbonate: in vitro and in vivo effects on gastric environment. Ther Apher Dial 19: 471-476, 2015.

18. Kodama Y, Kawabata K, Yoshida S, et al. Malt lymphoma simulating an extramedullary plasmacytoma of the stomach. Am J Med 107: 530-532, 1999.

19. Park CH, Lee SM, Kim TO, et al. Treatment of solitary extramedullary plasmacytoma of the stomach with endoscopic submucosal dissection. Gut Liver 3: 334-337, 2009.

20. Iwamuro M, Kanzaki H, Okada H. A white lesion in the stomach. Gastroenterology 150: 44-45, 2016.

21. Tsai YN, Tsai JW, Tai CM. Education and Imaging. Gastrointestinal: magnifying endoscopy for pseudomelanosis duodeni. J Gastroenterol Hepatol 31: 520, 2016.

22. Bisordi WM, Kleinman MS. Melanosis duodenii. Gastrointest Endosc 23: 37-38, 1976.

23. Namie S, Hamabe S, Kawatomi M, et al. Investigation of deposition of lanthanum on gastric mucosa in hemodialysis patients with lanthanum therapy. The Japanese Society for Dialysis Therapy 48: 169-177, 2015 (in Japanese, Abstract in English).